1. Introduction {#s0005}
===============

Extraovarian primary peritoneal carcinoma is a rare malignant epithelial tumor that develops from the peritoneum that lines the pelvis and abdomen. Clinically it is presented as an abdominal tumor without or minimal involvement of the ovaries and no identifiable primary tumor elsewhere ([@b0010]). The most frequent histological types are malignant mesothelioma and epithelial tumors of müllerian type, with only anecdotal reports of clear cell carcinoma (CCC). Only thirteen cases have been previously reported in the literature since 1990 ([@b0015], [@b0020]). In this report, we present a case of primary peritoneal clear cell carcinoma (PPCCC), as well as a review of the literature.

2. Case presentation {#s0010}
====================

A 48-year-old Caucasian woman consulted in our hospital because of progressive abdominal pain over the last seven months, with the initial diagnosis of renal-ureteral colic. She had no history of medical or surgical issues. Menopause was at 42 years of age, and she had two pregnancies that ended in a cesarean section. A transcervical myomectomy and tubal sterilization were also performed. She did not receive hormone replacement therapy, and familial history was uneventful. The patient had no history of endometriosis. On physical examination, she presented extreme obesity (BMI 45). An elastic, non-painful tumor was palpable, reaching the left costal margin, with no signs of ascites. The gynecological examination of external genitals was normal, and transvaginal ultrasound showed normal atrophic internal genitals.

The patient was admitted to the hospital for further examination. Serum tumor markers CA-19.9 and HE4 were negative, and the CA-125 level was 57 U/ml. The ROMA was a low risk for detecting ovarian epithelial cancer. Ultrasound and CT of the abdomen and pelvis ([Fig. 1](#f0005){ref-type="fig"}) revealed a 25x15 cm, well-defined cystic lesion with papillary projections, centrally located in the abdomen, with no evidence of pelvic or retroperitoneal lymph node metastasis. A moderate amount of ascites was evident (\<300 ml), and the examination of the gastrointestinal and genitourinary system was negative. The radiology report suggested a primary ovarian tumor versus peritoneal implant as the first option.Fig. 1Preoperative CT scan image.

The patient underwent an abdominal xiphopubic laparotomy that showed a large smooth cystic mass of 25--30 cm that occupied practically the entire abdomen ([Fig. 2](#f0010){ref-type="fig"}), firmly attached to the urinary bladder peritoneum and to the root of the mesentery. No more abdominal disease was seen, and there was no evidence of endometriosis. Both ovaries and fallopian tubes were grossly normal in appearance. The entire abdominal tumor was completely excised, with no visible residual disease. After its opening, approximately 3 L of serous fluid emanated and a multilocular tumor with papillary growth was evidenced. An intraoperative frozen section was taken from the papillae showing a papillary adenocarcinoma. Surgery was completed with a total hysterectomy with bilateral salpingo-oophorectomy and infra-colical omentectomy.Fig. 2A large cystic mass located in the urinary bladder peritoneum, firmly attached to the mesentery.

The postoperative period was normal, and the patient received the hospital discharge after 72 h. No further complications were reported.

After an extensive sampling of the lesion, tissue was formalin-fixed paraffin-embedded and stained with H&E. Immunohistochemistry was performed on tumor sections using the Dako Omnis GI100 Advance staining system (Dako/Agilent, Copenhagen, Denmark) by the standard avidin--biotin method (EnVision Flex^TM^ detection system; Dako/Agilent Technologies; Carpinteria, CA) using a panel of primary antibodies ([Table 1](#t0005){ref-type="table"}). We further performed next generation sequencing (NGS) analysis to detect molecular alterations using a custom gene panel previously published ([@b0005]). Target genes were: MMR associated genes (*MLH1*, *MSH6*, *MSH2*, *PMS2*), 44 genes related to ovarian and endometrium cancer (*PTEN*, *PIK3R1*, *CTNNB1*, *ARID1A*, *KRAS*, *TP53*, *PPP2R1A*, *BRCA1*, *BRCA2*, etc.), and regions in chromosomes 8 (targeting *MYC* amplification), 12 (*CHD4* amplification), 3 (*PIK3CA* amplification), 17 (*ERBB2* amplification) and 19 (*CCNE1* amplification).Table 1Panel of antibodies for the immunohistochemical analysis.AntibodyVendorCloneDilutionCK7DakoOV-TL 12/30PrediluteCK20DakoKs 20.8PrediluteCK34BE12Dako34BE12PrediluteBer-EP4DakoBer-EP4PrediluteCEADako11--7PrediluteCalretininDakoDAK-calret1PrediluteWT1Dako6F-H2Predilutep53DakoDO-7PrediluteERDakoEP1PrediluteNapsinALeicaNovocastraIP641:100AMACRDako13H4PredilutePAX8ProteinTechPolyclonal rabbit1:1200VimentinDakoV9Predilutep16BD BiosciencesG175-4051:100PTENDako6H2.11:100ARID1ASigmaHPA0054561:1500PD-L1Dako22C3PrediluteMLH1DakoES05PrediluteMSH2DakoE11PredilutePMS2DakoEP51PrediluteMSH6DakoEP49Predilute[^1]

The external surface of the tumor was smooth, of 25x23x17 cm in size. After completing its opening, we observed a multilocular tumor (0.1--20 cm) with papillary growth involving part of the inner wall of the largest cyst. The uterus and ovaries were grossly normal (right 2 × 1.6 × 0.7 cm and left 2.3 × 1.8 × 0.6 cm) as well as the fallopian tubes. Microscopically, the tumor displayed tubulocystic and papillary patterns with occasional solid areas. Tumor cells showed pale to clear and occasionally eosinophilic cytoplasm, with large atypical nuclei and prominent nucleoli. No lymph-vascular or perineural invasion was seen. Further, no areas of endometriosis were observed. Fallopian tubes showed normal histology, and both ovaries were atrophic without malignant neoplasia but bilateral serous adenofibromas (1 cm).

Immunohistochemical stainings showed positivity for CK7, NapsinA, AMACR, PAX8, vimentin, CK34BE12, Ber-EP4, p16, and CEA. Negative results were seen for CK20, calretinin, WT1, p53 (Wild-type), ER, and ARID1A (loss of expression in tumor cells; [Fig. 3](#f0015){ref-type="fig"}). These results supported the macroscopic and microscopic findings of a PPCCC. Furthermore, PD-L1 was negative, and PTEN and mismatch repair proteins (MLH1, MSH2, PMS2, and HSH6) were preserved. NGS results showed a pathogenic deletion in *ARID1A -*p.Ala162GlyfsTer234 (c.485_495del)-. In addition, two germline mutations were observed in both *MKI67* (L1806V) and *BRCA2* (T1915M), and somatic mutations in *GSDMB* (V197A) and *KMT2C* (S772L/K339N/T316S/L291F).Fig. 3Loss of nuclear expression for ARID1A in tumor cells (40x magnification).

The final diagnosis was PPCCC, FIGO stage IIIC (T3c-N0-M0) ([@b0025]). The clinic case was discussed in our multidisciplinary committee to decide the adjuvant treatment plan.

The patient received systemic chemotherapy with carboplatin (6 AUC) and paclitaxel (175 mg/m^2^) every 3 weeks (×4 cycles).

The computed tomography (CT), after a follow-up of eight months since the last cycle of chemotherapy, showed suspicious images of peritoneal implants predominantly in the right diaphragmatic cupule. Serum tumor markers were negative. The patient underwent a diagnostic laparoscopic that corroborated the CT findings, and the recurrence was confirmed histologically. Currently, the patient has just completed another 6 cycles of chemotherapy with carboplatin (6 AUC) and paclitaxel (175 mg/m^2^) every 3 weeks. The last CT (28 months after initial surgery) provided the radiological stability of the implants.

3. Discussion and conclusions {#s0015}
=============================

We report the clinicopathological and immunohistochemical findings of a new case of PPCCC. Histologically, this tumor showed the typical features of a CCC, being the ovary or endometrium, the most frequent locations. In fact, they would be the primary tumor location to exclude due to the rarity in the peritoneum. The current case fulfills the diagnostic criteria for primary peritoneal tumors ([@b0010]).

According to previous literature ([@b0015], [@b0020]), the average age of the patients was 53 years (range from 37 to 67 years), and about one third had a past gynecological history of endometriosis. They usually present with progressive abdominal pain and distention, as a single mass with an average size of 11 cm.

Several tumors and tumor-like lesions share origin from the so-called secondary müllerian system, that is, the pelvic and lower abdominal mesothelium and the subjacent mesenchyme of females ([@b0030]). Currently, the most accepted theories regarding the origin of CCC in the peritoneum are müllerian metaplasia and endometriosis with malignant transformation. However, the latter occurs at extraovarian sites in only 1.6% of the cases ([@b0035]). Also, estrogen dependence has been suggested due to its association with endometriosis, adenomyosis, and endometrial carcinoma ([@b0040]). In the current case, despite extensive sampling of the resected specimens, we were not able to demonstrate endometriosis, in contrast with previously reported cases ([@b0015]), and the endometrium was atrophic. In addition, ER expression was absent in agreement with three out of four reported cases ([@b0015], [@b0020]). Our patient had two previous cesareans, which could be a fact to consider in terms of the possible peritoneal dissemination of endometriosis. Past history of coexistent endometrial hyperplasia or endometrioid carcinoma was demonstrated in only four of thirteen previously reported patients ([@b0015]). Therefore, we postulate that PPCCC is not necessarily estrogen-dependent neoplasia. Moreover, this histology is very unlikely to have a genetic predisposition ([@b0045]). It is known that in the ovary, CCC usually develops from endometriotic cysts ([@b0055]). Interestingly, Kim et al ([@b0050]) by using NGS showed increased mutations in *PIK3CA, ARID1A,* and *KRAS* in ovarian CCC regardless of the association with endometriosis.

Our case presented a pathogenic deletion in *ARID1A,* leading to a loss of ARID1A expression. In addition, two germline mutations in *MKI67* and *BRCA2*, which appear in the databases as benign, although the population frequency of both is less than 1%. Finally, it also presented a series of somatic mutations in *GSDMB* and *KMT2C*, which appear as unreported or of uncertain significance. Of note, in none of the previously published PPCCC cases, these molecular analyses were performed; therefore, no comparison is possible.

Recent studies support the key role of the immune system in modulating tumorigenesis and tumor clearance in several neoplasias, including endometrial and ovarian CCC ([@b0060]). One main immune checkpoint pathway is mediated by programmed cell death 1 (PD-1), which is expressed on activated lymphocytes and its ligand (PD-L1). It is upregulated on antigen-presenting cell types in response to cytokine mediators in a normal immune response. The success of PD-1 and PD-L1 inhibitor therapy in numerous malignancies has led to recent studies in ovarian and endometrial tumors, including cancers with clear cell histology. The results support the role of PD-L1 expression as a potential biomarker for PD-1/PD-L1 inhibitor response regardless of mismatch repair (MMR) status ([@b0060]). In the current case, we also assessed the expression of PD-L1 and MMR genes labeling in tumor cells showing negativity for PD-L1 and the MMR proteins preserved. Therefore, targeted immunotherapy was not an option for our patient.

Histologically, the main differential diagnosis should be made first with peritoneal serous carcinoma, especially at younger ages due to genetic predisposition (germinal mutations in BRCA1/2) in patients with a personal family history of ovarian or breast carcinomas.

Previous PPCCC patients received treatment similar to ovarian carcinoma showing diverse clinical responses ([@b0015], [@b0020]). Despite a few reported cases, it is considered a tumor with poor prognosis (recurrence or death from the disease between 4 and 32 months), depending on the clinicopathological stage and the amount of residual tumor after treatment. In support, our patient presented peritoneal recurrence eight months after completing chemotherapy despite non-residual tumor after debulking surgery.

In conclusion, CCC is a very rare tumor in the peritoneum. It may also be influenced by its lack of recognition, being diagnosed as another neoplasia more frequent in this location. Therefore, in addition to the typical histological findings, immunohistochemistry is a very useful tool for the main differential diagnosis.

Currently, promising data is available regarding response to PD-1/PD-L1 inhibitor therapy in a subset of patients with CCC. However, further research addressing novel biomarkers and treatment strategies are necessary to improve local control and decrease mortality for these patients.
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